[Problems in the therapy of ovarian carcinoma with gestagen-acting hormones].
Our experience concerning the effectivity of progestogens (Noräthisteron 50 mg per os daily) in cases of advanced ovarian cancer is reported. Group 1 (25 pat.) suffering from less sensitive ovarian cancer was treated with cytotoxic drugs and hormones. The survival chance of combined hormonal and tumourchemotherapy was nearly 40% better than the survival chance with chemotherapy alone. In Group 2 (14 pat.) suffering from secondary resistant ovarian cancer chemotherapy was stopped, but the patients received hormones only. There were no better survival rate in this group. The biomolecular background is explained.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D009640:Norethindrone / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000970:Antineoplastic Agents; D009640:Norethindrone
Zur Problematik der Therapie mit gestagenwirkenden Hormonen beim Ovarialkarzinom.